779.67
-1.77(-0.23%)
Currency In USD
| Previous Close | 781.44 |
| Open | 775 |
| Day High | 780.88 |
| Day Low | 770 |
| 52-Week High | 821.11 |
| 52-Week Low | 476.49 |
| Volume | 586,525 |
| Average Volume | 944,351 |
| Market Cap | 81.01B |
| PE | 18.78 |
| EPS | 41.51 |
| Moving Average 50 Days | 759.85 |
| Moving Average 200 Days | 628.27 |
| Change | -1.77 |
If you invested $1000 in Regeneron Pharmaceuticals, Inc. (REGN) 10 years ago, it would be worth $1,969.91 as of February 21, 2026 at a share price of $779.67. Whereas If you bought $1000 worth of Regeneron Pharmaceuticals, Inc. (REGN) shares 5 years ago, it would be worth $1,692.8 as of February 21, 2026 at a share price of $779.67.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)
GlobeNewswire Inc.
Feb 19, 2026 12:00 PM GMT
FOP is an ultra-rare genetic disorder characterized by abnormal bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability If approved, garetosmab would be the first and only availab
EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases
GlobeNewswire Inc.
Feb 02, 2026 12:00 PM GMT
New presentations include final 64-week results from the Phase 3 QUASAR trial in patients with retinal vein occlusion, as well as full primary results from the Phase 3b ELARA trial in patients treated with monthly dosingTARRYTOWN, N.Y., Feb. 02, 202
Nation’s Top 40 High School Scientists to Compete for $1.8 Million in Awards at the Prestigious Regeneron Science Talent Search
GlobeNewswire Inc.
Jan 21, 2026 5:00 PM GMT
The Regeneron Science Talent Search Honors America’s Brightest Young Scientists Advancing Discovery and InnovationTARRYTOWN N.Y. and WASHINGTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Society for Science (the Society) and Regeneron today announced the t